FAMICORD AG (V3V.DE) Stock Fundamental Analysis
Europe - FRA:V3V - DE000A0BL849 - Common Stock
5.9 EUR
-0.05 (-0.84%)
We assign a fundamental rating of 3 out of 10 to V3V. V3V was compared to 32 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of V3V have multiple concerns. V3V is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
V3V had positive earnings in the past year.
V3V had a positive operating cash flow in the past year.
In multiple years V3V reported negative net income over the last 5 years.
V3V had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.61%, V3V is doing worse than 68.75% of the companies in the same industry.
V3V has a Return On Equity (10.63%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.61% | ||
| ROE | 10.63% | ||
| ROIC | N/A |
ROA(3y)-7.04%
ROA(5y)-3.48%
ROE(3y)-60.2%
ROE(5y)-34.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
V3V's Profit Margin of 3.20% is fine compared to the rest of the industry. V3V outperforms 62.50% of its industry peers.
Looking at the Gross Margin, with a value of 36.66%, V3V is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
In the last couple of years the Gross Margin of V3V has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 3.2% | ||
| GM | 36.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.67%
GM growth 5Y-8.9%
2. Health
2.1 Basic Checks
V3V does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for V3V has been increased compared to 1 year ago.
The number of shares outstanding for V3V has been increased compared to 5 years ago.
Compared to 1 year ago, V3V has an improved debt to assets ratio.
2.2 Solvency
V3V has an Altman-Z score of 0.59. This is a bad value and indicates that V3V is not financially healthy and even has some risk of bankruptcy.
V3V has a Altman-Z score of 0.59. This is in the lower half of the industry: V3V underperforms 75.00% of its industry peers.
The Debt to FCF ratio of V3V is 2.09, which is a good value as it means it would take V3V, 2.09 years of fcf income to pay off all of its debts.
V3V's Debt to FCF ratio of 2.09 is amongst the best of the industry. V3V outperforms 96.88% of its industry peers.
A Debt/Equity ratio of 0.56 indicates that V3V is somewhat dependend on debt financing.
The Debt to Equity ratio of V3V (0.56) is better than 81.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | 2.09 | ||
| Altman-Z | 0.59 |
ROIC/WACCN/A
WACC6.43%
2.3 Liquidity
A Current Ratio of 0.76 indicates that V3V may have some problems paying its short term obligations.
With a Current ratio value of 0.76, V3V is not doing good in the industry: 71.88% of the companies in the same industry are doing better.
A Quick Ratio of 0.70 indicates that V3V may have some problems paying its short term obligations.
V3V has a Quick ratio (0.70) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.76 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
V3V shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 109.51%, which is quite impressive.
Looking at the last year, V3V shows a small growth in Revenue. The Revenue has grown by 7.73% in the last year.
The Revenue has been growing by 30.44% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)109.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
Revenue 1Y (TTM)7.73%
Revenue growth 3Y57.65%
Revenue growth 5Y30.44%
Sales Q2Q%8.91%
3.2 Future
The Earnings Per Share is expected to grow by 30.68% on average over the next years. This is a very strong growth
Based on estimates for the next years, V3V will show a small growth in Revenue. The Revenue will grow by 2.88% on average per year.
EPS Next Y58.33%
EPS Next 2Y38.44%
EPS Next 3Y34.2%
EPS Next 5Y30.68%
Revenue Next Year9.33%
Revenue Next 2Y8.01%
Revenue Next 3Y7.82%
Revenue Next 5Y2.88%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 42.14 indicates a quite expensive valuation of V3V.
71.88% of the companies in the same industry are cheaper than V3V, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of V3V to the average of the S&P500 Index (27.90), we can say V3V is valued expensively.
V3V is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.14 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, V3V is valued a bit more expensive than the industry average as 68.75% of the companies are valued more cheaply.
Based on the Price/Free Cash Flow ratio, V3V is valued a bit cheaper than the industry average as 68.75% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.6 | ||
| EV/EBITDA | 12.41 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as V3V's earnings are expected to grow with 34.20% in the coming years.
PEG (NY)0.72
PEG (5Y)N/A
EPS Next 2Y38.44%
EPS Next 3Y34.2%
5. Dividend
5.1 Amount
V3V does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:V3V (10/3/2025, 7:00:00 PM)
5.9
-0.05 (-0.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.9%
Inst Owner ChangeN/A
Ins Owners58.45%
Ins Owner ChangeN/A
Market Cap104.08M
Analysts45.71
Price Target7.65 (29.66%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.38%
PT rev (3m)15.38%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.14 | ||
| Fwd PE | N/A | ||
| P/S | 1.29 | ||
| P/FCF | 11.6 | ||
| P/OCF | 8.59 | ||
| P/B | 4.29 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.41 |
EPS(TTM)0.14
EY2.37%
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)0.51
FCFY8.62%
OCF(TTM)0.69
OCFY11.64%
SpS4.57
BVpS1.38
TBVpS-1.68
PEG (NY)0.72
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.61% | ||
| ROE | 10.63% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 3.2% | ||
| GM | 36.66% | ||
| FCFM | 11.13% |
ROA(3y)-7.04%
ROA(5y)-3.48%
ROE(3y)-60.2%
ROE(5y)-34.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.67%
GM growth 5Y-8.9%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | 2.09 | ||
| Debt/EBITDA | 1.65 | ||
| Cap/Depr | 35.61% | ||
| Cap/Sales | 3.89% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 147.25% | ||
| Profit Quality | 347.6% | ||
| Current Ratio | 0.76 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 0.59 |
F-Score7
WACC6.43%
ROIC/WACCN/A
Cap/Depr(3y)60.39%
Cap/Depr(5y)47.49%
Cap/Sales(3y)7.53%
Cap/Sales(5y)6.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)109.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
EPS Next Y58.33%
EPS Next 2Y38.44%
EPS Next 3Y34.2%
EPS Next 5Y30.68%
Revenue 1Y (TTM)7.73%
Revenue growth 3Y57.65%
Revenue growth 5Y30.44%
Sales Q2Q%8.91%
Revenue Next Year9.33%
Revenue Next 2Y8.01%
Revenue Next 3Y7.82%
Revenue Next 5Y2.88%
EBIT growth 1Y97.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year562.86%
EBIT Next 3Y110.83%
EBIT Next 5Y79.58%
FCF growth 1Y198.46%
FCF growth 3Y20.6%
FCF growth 5Y6%
OCF growth 1Y520.19%
OCF growth 3Y37.37%
OCF growth 5Y14.78%